Palvella Shares Rise After FDA Grants Rolling Review for QTORIN Rapamycin
Palvella Therapeutics shares climbed after the FDA granted a rolling review of the company’s New Drug Application for QTORIN rapamycin, its lead candidate for treating microcystic lymphatic malformations. The decision, paired with existing Breakthrough Therapy, Orphan Drug and Fast Track designations and a newly flagged European patent extending pr…